The invention relates to the use of a combination of at least two markers
that are selected from among Uromodulin, MAC2BP, AGP1 and Cathepsin A,
for the in vitro detection of fibrotic alterations. In addition, the
invention relates to a kit for determining the levels of said markers in
a biological sample.